Creatine Monohydrate

Clinical Summary

Creatine monohydrate is the most extensively studied dietary supplement in history, with 500+ RCTs spanning 30+ years and a safety record matched by few compounds. It is a naturally occurring amino acid derivative (synthesized from arginine, glycine, and methionine) that functions as the body's primary rapid energy buffer via the phosphocreatine/creatine kinase system.

Who benefits most: Resistance-trained individuals of any age (5/5), elderly at risk of sarcopenia (5/5), vegetarians/vegans (largest cognitive + muscle gains due to lower baseline stores), sleep-deprived individuals (cognitive protection), and potentially those with treatment-resistant depression, TBI, or type 2 diabetes.

Key mechanism: Creatine is phosphorylated to phosphocreatine (PCr) in tissues with high energy demand (skeletal muscle ~95%, brain, heart). PCr regenerates ATP 10-12x faster than oxidative phosphorylation during high-intensity efforts. Supplementation saturates muscle stores from ~120 to ~150 mmol/kg dry weight.

Endogenous synthesis: ~1-2 g/day via two-step process: AGAT (kidney) produces guanidinoacetate, then GAMT (liver) methylates it using SAM. Cofactors: Folate, Vitamin-B12, Choline. Dietary sources: red meat, fish (~1-2 g/day in omnivores; <0.5 g/day in vegetarians).

Bottom line: Universal recommendation for anyone doing resistance training. Among the safest, cheapest, and most evidence-backed supplements available. Non-responders (20-30%) exist, likely due to already-saturated stores or SLC6A8 transporter variants.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = causal relationship (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type (e.g., AHE type caps at 2/5).

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal-to-human | OA=Observational | NE=No evidence BH: 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial signal | AVOID Contraindicated

Star legend: 5/5=Multiple large RCTs + meta-analyses | 4/5=Several human RCTs | 3/5=Some human pilot data | 2/5=Animal/very limited human | 1/5=None/debunked

Prescribing

Dosing Table

Formulation Table

Key takeaway: Monohydrate (standard or micronized) remains the gold standard. All alternative forms cost more and offer no proven advantage. ISSN position stand explicitly states monohydrate is the reference standard (PMID: 28615996).

Condition-Specific Protocols

Sarcopenia Prevention Protocol

Evidence: 5/5 | Key PMIDs: 24576864, 30959901, 40673730

Phase 1: Initiation (Weeks 1-4)

• Dose: 5 g/d with breakfast (skip loading in elderly to avoid GI issues)
• Start resistance training 2-3x/wk simultaneously
• Baseline: DEXA or BIA for body composition, grip strength, eGFR

Phase 2: Therapeutic (Weeks 5-24)

• Continue 5 g/d with protein-containing meal (20-30 g protein)
• Combine with Vitamin D3 (2000-4000 IU/d if deficient) and Protein (1.2-1.6 g/kg/d)
• Monitor: grip strength, chair stand test every 3 mo; eGFR at 3 mo

Phase 3: Maintenance (Week 24+)

• Continue 5 g/d indefinitely; no cycling needed
• Functional assessments every 6 mo; annual DEXA

Expected Outcomes: +0.9-1.4 kg lean mass, +8-12% strength, improved gait speed (+0.1 m/s), reduced falls risk (indirect) Stop/Reassess: If no measurable benefit after 24 wk with adherent RT; if eGFR drops >30%

TBI / Concussion Recovery Protocol

Evidence: 4/5 | Key PMIDs: 16917449, 41504207, 40440029

Acute Phase (Days 1-7): 20 g/d divided into 4 doses; start within 24-48 h of injury Maintenance (Weeks 2-24): 10-20 g/d (adults) or 0.4 g/kg/d (pediatric) Duration: Minimum 6 months for moderate-severe TBI

Expected Outcomes: 30-50% reduction in post-concussive symptoms (headache, dizziness, fatigue); faster neurocognitive recovery Pre-loading (athletes at risk): 5 g/d during season may provide neuroprotection if concussion occurs Stop/Reassess: Standard neurological follow-up; no creatine-specific adverse effects reported in TBI studies

T2D / Metabolic Syndrome Protocol

Evidence: 3/5 | Key PMIDs: 19437111, 40944248

Initiation: 5 g/d (no loading) with largest meal; must pair with resistance training Monitoring: Fasting glucose weekly (first 2 wk), HbA1c every 3 mo, eGFR every 6 mo Drug adjustment: May need to reduce metformin or sulfonylurea doses by 10-20% due to improved insulin sensitivity Expected Outcomes: HbA1c -0.3-0.7%, fasting glucose -10-20 mg/dL, +1-2 kg lean mass over 12 wk

Safety

Interactions Table

Contraindications

• Absolute: Severe renal impairment (eGFR <30) — precautionary, not proven harm; known creatine allergy (extremely rare)
• Relative: Moderate renal impairment (eGFR 30-59) — use 2-3 g/d with monitoring; active nephrotoxic drug therapy

Adverse Effects

At maintenance dose (3-5 g/d): Essentially none confirmed in RCTs. Over 1,100+ safety studies spanning 30+ years.

NOT caused by creatine (debunked): Kidney damage (PMID: 21394604, 41199218), liver damage (PMID: 12701815), dehydration (PMID: 14608430), hair loss (PMID: 40265319), hormonal disruption (PMID: 33557850)

FAERS Signal Table (from BioMCP)

FAERS interpretation: Total 927 reports, but only 1 report where creatine was the sole suspect drug (coma + GERD + aspiration pneumonia — a single serious case with unclear confounders). The FAERS profile is overwhelmingly noise from multi-ingredient supplement products and concomitant medications. No FDA label warnings exist. This is consistent with creatine's exceptional safety profile in controlled trials.

Monitoring Table

Special Populations

Pregnancy & Lactation

• Status: 2/5 Insufficient data — NOT recommended for routine use
• Context: No teratogenic effects in animal models; creatine naturally present in breast milk (~15-20 μmol/L); emerging research suggests potential fetal neuroprotection in high-risk pregnancies (PMID: 40371844)
• Recommendation: Obtain creatine from dietary sources during pregnancy/lactation; supplementation only under medical supervision in research settings

Pediatric (<18 y)

• <16 y: Not recommended for general use; only under medical supervision for muscular dystrophy or TBI
• 16-18 y: Acceptable for competitive athletes at 3-5 g/d with medical/parental supervision
• Position statements: AAP cautions against use <18; ISSN suggests possible use 16-18 with supervision

Renal Impairment

Synergies & Stacking

Known antagonisms: None well-established. High-dose caffeine (>400 mg) showed possible antagonism in one 1996 study (Vandenberghe) but has NOT been replicated; current consensus is no interaction.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No pharmacogenomic studies found for CYP, MTHFR, COMT, APOE, or VDR interactions with creatine (searched 2024-2026; PMID search returned 0 results for "creatine pharmacogenomics"). Creatine's metabolism is primarily non-CYP (creatine kinase + spontaneous degradation to creatinine).

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Overwhelmingly positive across all communities (~10,000+ reports). Creatine is one of the rare supplements with near-universal community endorsement backed by clinical evidence.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: None. Creatine is too cheap for MLM margins (~$0.05/g for monohydrate).
• Influencer concentration: Broad consensus, not driven by 1-2 influencers. Every major fitness/nutrition authority recommends it.
• Astroturfing signals: None detected. Marketing is mostly from alternative formulations (HCl, buffered) trying to compete with cheap monohydrate.
• Commercial bias: Alternative formulations (HCl, Kre-Alkalyn, CEE) are marketed aggressively with unsupported superiority claims to justify 3-5x price premiums.

Folk vs Clinical Reality Check

Community experience aligns remarkably well with clinical data — unusual for supplements. The strength/mass gains users report match RCT effect sizes closely. The main divergence is the persistent hair loss fear (driven by a single 2009 study with N=20 that has now been directly refuted by a 2025 RCT, PMID: 40265319). The community has largely moved past this concern. Cognitive benefits are frequently reported on r/Nootropics but users often expect dramatic effects; the clinical reality is modest improvement, primarily under metabolic stress or in those with low baseline stores.

Deep Dive: Mechanisms & Research

Key Mechanisms with Clinical Translation

Phosphocreatine energy buffer (5/5 translation): The creatine kinase reaction (PCr + ADP + H⁺ → Creatine + ATP) provides the fastest ATP regeneration pathway — critical for the first 10 seconds of high-intensity effort. Supplementation increases muscle PCr stores by ~20-40%, directly extending high-intensity work capacity. This is the primary mechanism for ALL performance benefits.

Cell volumization and anabolic signaling (4/5 translation): Creatine uptake increases intracellular water, triggering mTOR pathway activation and satellite cell proliferation. This is why creatine enhances hypertrophy beyond what strength gains alone would predict.

GLUT4 translocation (3/5 translation): Creatine enhances insulin-independent glucose uptake via GLUT4 translocation, partially explaining metabolic benefits in T2D. This mechanism also underlies enhanced glycogen storage.

Brain bioenergetics (3/5 translation): Brain creatine elevation (5-15% with chronic supplementation) supports neuronal ATP availability. Benefits most apparent when brain energy metabolism is stressed (sleep deprivation, TBI, aging, vegetarian diet). Slow brain penetration (4-6 weeks) explains why cognitive benefits require longer supplementation than muscle benefits.

Gut microbiota-creatine axis (2/5 emerging): A 2026 Cell Metabolism paper (PMID: 41923613) showed gut microbiota can alleviate depression by remodeling gut-brain energy metabolism via creatine biosynthesis pathways. This is early-stage but represents a novel mechanism linking gut health, creatine, and mood.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Notable: 253 total registered trials, 35 currently recruiting. Active research expanding into cancer cachexia, stroke recovery, Down syndrome, and bipolar disorder — all new frontiers since the original file.

Regulatory Status (from BioMCP)

• FDA: Not approved as a drug. GRAS (Generally Recognized as Safe) as dietary ingredient. No FDA label warnings. DrugBank ID: DB00148.
• EMA: Not approved; no data in EMA registry.
• WADA: Not prohibited. Permitted in all sports at all doses.
• ISSN: Gold-standard ergogenic supplement (position stand 2017, updated review 2026).
• EFSA: Safe at 3 g/day for general population.
• Regulatory context: Creatine has never been submitted for drug approval because it is unpatentable (natural compound), cheap, and widely available as a dietary supplement. The lack of FDA approval reflects commercial non-viability as a drug, not safety concerns.

Ataraxia Verdict (as of 2026-04-15)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

Fallacies detected:

• Appeal to popularity: "Everyone takes creatine, so it must work" — but in this case, the evidence genuinely supports popular use. Rare alignment.
• Alternative formulation marketing: Classic cherry-picking and appeal to novelty. HCl, Kre-Alkalyn, and CEE are marketed with unsupported superiority claims. Head-to-head RCTs show NO advantage over cheap monohydrate.
• Generalization from athletes to disease populations: Much of the disease-specific protocol evidence (celiac, IBD, leaky gut, SIBO) in the prior version was extrapolated from sarcopenia data, which is reasonable but should be labeled as such.
• Non-responder dismissal: The 20-30% non-responder rate is real and underemphasized in marketing. SLC6A8 variants are a likely mechanism (PMID: 41719210).

No major fallacies in the core claims. Creatine is the rare supplement where marketing claims are largely supported by evidence.

Evidence Gaps

1. Women's health: Severely underresearched until 2024-2025. First comprehensive review only published in 2025 (PMID: 40371844). Menstrual cycle effects on retention, pregnancy safety, menopause-specific dosing all unknown.
2. Long-term safety (>10 y): Safe up to 10 years in case series, but no 20-30 year systematic data.
3. Genetic non-responders: 20-30% show minimal benefit; SLC6A8 common variant role emerging but not clinically actionable yet.
4. Neurodegenerative diseases: Parkinson's large RCT was negative; Alzheimer's trial (NCT05383833) just completed but results pending. Brain penetration remains limiting.
5. Cancer cachexia: Two Phase 3 trials recruiting (prostate, breast) — first rigorous evaluation.
6. Longevity: Animal data shows +9% lifespan in mice (PMID: 17416440); no human longevity data.
7. Gut microbiome interaction: 2026 Cell Metab paper (PMID: 41923613) opens new research direction.

Bias Flags (Mode 4: First Principles)

• Core mechanism is rock-solid: PCr/CK system is fundamental biochemistry, not speculative.
• Clinical translation proven: Mechanism → RCT → meta-analysis chain complete for muscle/strength outcomes.
• Non-responder biology: Likely real (genetic + dietary baseline), not compliance artifact.
• Brain benefits require context: Population-specific (vegetarians, elderly, stressed); don't generalize to all adults.
• Disease-specific protocols often extrapolated: Many condition-specific recommendations lack direct RCTs and are based on mechanistic reasoning from sarcopenia data.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Primarily from alternative formulation manufacturers (Con-Cret, Kre-Alkalyn). Monohydrate is too cheap for aggressive marketing; the competition is in convincing consumers to pay 3-5x more for unproven forms.
• Influencer economics: Fitness influencers universally recommend creatine, but this aligns with evidence. No undisclosed sponsorship patterns detected for monohydrate specifically; some sponsored content for proprietary forms.
• Counter-narrative manipulation: The "kidney damage" myth persists despite overwhelming contrary evidence. Source is unclear — possibly clinical labs flagging elevated creatinine without understanding the mechanism.
• Cui bono summary: Monohydrate manufacturers win (but margins are thin). Alternative form manufacturers win more. Nobody wins from the kidney damage myth — it appears to be genuine misinformation, not orchestrated.
• Red team highlight: The most concerning angle is non-responder management — 20-30% of users spend money on a supplement that may provide minimal benefit, with no routine way to predict response.

Decision Support (Mode 3: Clarity Compass)

• General health utility: 9/10 — one of the most universally applicable supplements
• Opportunity cost: Extremely low ($0.05-0.15/g; ~$3-5/month at maintenance)
• Hell Yes test (Sivers): YES for anyone doing resistance training; YES for elderly; YES for vegetarians
• Regret minimization: In 5 years, you would regret NOT trying creatine more than trying it
• Verdict: ADD — Strong evidence, broadly applicable, minimal downside, exceptionally cheap, remarkable safety profile

Bottom Line

Creatine monohydrate is the single most evidence-backed dietary supplement available. With 500+ RCTs, 20+ meta-analyses, and 30+ years of safety data, its efficacy for muscle strength, lean mass, and high-intensity performance is beyond reasonable doubt. Cognitive benefits are real but population-specific (vegetarians, elderly, sleep-deprived). Emerging evidence supports roles in TBI recovery, depression augmentation, and metabolic health. Safety profile is exceptional — no confirmed organ damage in healthy individuals despite decades of scrutiny. The main limitations are the 20-30% non-responder rate (possibly SLC6A8-related) and severely underresearched women's health applications. At $3-5/month, the cost-benefit ratio is unmatched in supplementation.

Practical Notes

Brands & Product Selection

• Creapure (AlzChem, Germany): Pharmaceutical-grade (>99.99% purity). Gold standard for purity; look for Creapure logo on third-party brands. NSF Certified for Sport and Informed-Choice options available.
• Any micronized monohydrate from reputable manufacturer (NOW, Optimum Nutrition, BulkSupplements, Thorne) is adequate.
• Red flags: Proprietary blends hiding creatine dose; "creatine matrix" or multi-form products at premium prices; liquid creatine (degrades rapidly).
• Third-party testing: NSF Certified for Sport or Informed-Choice tested options recommended for competitive athletes.

Storage & Handling

• Dry powder: Stable 2-3 years in sealed container at room temperature. Avoid humidity and heat.
• Pre-mixed liquid: Use within 1-2 hours. Degrades to creatinine in solution over time.
• Degradation indicators: Clumping (moisture exposure); yellowing (heat damage). Discard if either observed.

Palatability & Compliance

• Unflavored monohydrate is virtually tasteless with slight sweet note.
• Mix in warm (not hot) water for best dissolution; cold water OK for micronized forms.
• Excellent in: protein shakes, juice, smoothies, oatmeal.
• AVOID: hot coffee/tea (>60C degrades to creatinine), pre-mixing days in advance.
• Compliance tip: Take at same time daily with an existing meal habit. Creatine works via saturation, not acute dosing — consistency matters more than timing.

Exercise & Circadian Timing

• Post-workout has slight edge for muscle uptake due to exercise-induced insulin sensitivity and transporter upregulation (PMID: 16807907).
• Any consistent time is acceptable once stores are saturated (after 4 weeks maintenance).
• No cycling needed. Continuous daily use is optimal. Muscle creatine returns to baseline 4-6 weeks after stopping.
• Not a stimulant. Safe for evening use; no evidence of sleep disruption. Some users report improved sleep quality.

Reference Ranges (Expected Biomarker Changes)

Cost

• Monohydrate (standard/micronized): ~$0.05-0.18/g → $0.15-0.90/day at 5 g/d → $4.50-27/month
• Creapure brand: ~$0.10-0.20/g → $0.50-1.00/day → $15-30/month
• Bulk purchase (1-5 kg): Drops to $0.02-0.05/g → $2-8/month (best value)
• Cost-effectiveness: Among the cheapest effective supplements available. Monthly cost less than a single coffee.

What We Don't Know

• Long-term safety beyond 10 years of continuous supplementation (longest systematic data ~5-10 y)
• Optimal dosing for women across menstrual cycle, pregnancy, and menopause
• Genetic basis of non-response — why 20-30% don't benefit; SLC6A8 common variants are emerging suspect
• Brain penetration optimization — creatine BBB transport is limited; better CNS delivery could unlock neurodegeneration applications
• Cancer outcomes — Phase 3 trials for prostate and breast cancer cachexia recruiting; no results yet
• Ischemic stroke recovery — trial recruiting (NCT06576466); novel application
• Gut microbiome interactions — emerging evidence that microbial creatine metabolism affects mood (PMID: 41923613); mechanism unclear
• Ideal start age for longevity benefit — mouse data shows lifespan extension; when should humans start for maximum healthspan?
• Down syndrome applications — trial recruiting (NCT07213063); first rigorous evaluation
• Long COVID mechanism — single positive trial (PMID: 38684388); needs replication
• Fibromyalgia — trial enrolling (NCT06674708); no RCT data yet
• Why the Parkinson's trial failed — dose too low? Started too late? Wrong subtype? Blood-brain barrier limitation?
• Alzheimer's trial results — NCT05383833 completed 2024; results not yet published

References

Systematic Reviews & Meta-Analyses

1. Lanhers C et al. (2017) Creatine and upper limb strength: systematic review and meta-analysis. Sports Med 47(1):163-173. PMID: 27328852. ES=0.36 across 39 studies, N=1,089.
2. Branch JD (2003) Creatine and body composition/performance: meta-analysis. IJSNEM 13(2):198-226. PMID: 12945830. +0.9-2.2 kg lean mass, +8-14% strength.
3. Devries MC, Phillips SM (2014) Creatine in older adults: meta-analysis. MSSE 46(6):1194-1203. PMID: 24576864. +1.37 kg lean mass, +24% leg press in >50 y (22 RCTs, N=721).
4. Avgerinos KI et al. (2018) Creatine and cognitive function: systematic review. Exp Gerontol 108:166-173. PMID: 29704637. d=0.35; benefits in elderly, vegetarians, sleep-deprived.
5. Kim HJ et al. (2011) Creatine safety: meta-analysis. Amino Acids 40(5):1409-1418. PMID: 21394604. No effect on GFR in healthy individuals (N=900+).
6. Naeini EK et al. (2025) Creatine and kidney function: systematic review and meta-analysis. BMC Nephrol. PMID: 41199218. Confirms creatine does not impair renal function.
7. Marshall S et al. (2026) Creatine and cognition in aging: systematic review. Nutr Rev. PMID: 40971619.
8. Wang Z et al. (2026) Protein vs creatine vs omega-3 for muscle: network meta-analysis. Nutrients. PMID: 41901084. 8a. Prokopidis K, Giannos P, Forbes SC, Candow DG et al. (2023) Creatine and memory in healthy individuals: systematic review and meta-analysis of RCTs. Nutrition Reviews 81(4):416-427. PMID: 35984306. 10 RCTs pooled; SMD=0.29 overall memory improvement; strongest effect in older adults (66-76 y, SMD=0.88). Dose range 2.2–20 g/d; dose did NOT significantly moderate effect — supporting efficacy across the full evidence-based dose spectrum. 8b. Candow DG, Moriarty T (2024) Creatine monohydrate for muscle, bone, and brain in older adults — hope or hype? Curr Osteoporos Rep 23(1):1. PMID: 39509039. Self-critical review from the Candow lab: "hope" for muscle/cognition, "hype" for bone.

Position Stands & Authoritative Reviews

9. Kreider RB et al. (2017) ISSN position stand: creatine safety and efficacy. JISSN 14:18. PMID: 28615996. "Most effective ergogenic nutritional supplement currently available."
10. Antonio J et al. (2021) Common creatine misconceptions: what evidence shows. JISSN 18(1):13. PMID: 33557850. Debunks kidney, hair, dehydration myths.
11. Antonio J et al. (2025) Part II: Common creatine misconceptions. JISSN. PMID: 39720835.
12. Kerksick C et al. (2026) Emerging evidence supporting creatine as ergogenic aid. JISSN. PMID: 41870601.
13. Candow DG et al. (2025) Creatine for older adults and clinical populations. JISSN. PMID: 40673730.
14. Smith-Ryan AE et al. (2025) Creatine in women's health: menstruation through menopause. JISSN. PMID: 40371844.
15. Longobardi I et al. (2025) Common safety concerns regarding creatine. Front Nutr. PMID: 41404326.
16. Shao A, Hathcock JN (2006) Risk assessment for creatine monohydrate. Regul Toxicol Pharmacol 45(3):242-251. PMID: 16814585. NOAEL at 25 g/d.

Landmark RCTs

17. Volek JS et al. (1997) Creatine enhances high-intensity resistance exercise. JADA 97(7):765-770. PMID: 9216553. +18% bench reps, +22% total work.
18. Burke DG et al. (2003) Creatine + RT on IGF-1 in young adults. IJSNEM 13(3):359-373. PMID: 14669935. +3.7 kg lean tissue vs +1.1 kg placebo.
19. Green AL et al. (1996) Carbohydrate augments muscle creatine accumulation. Am J Physiol 271:E821-826. PMID: 8944667. +60% uptake with 93 g carbs (landmark study).
20. Spillane M et al. (2009) Creatine ethyl ester inferior to monohydrate. JISSN 6:6. PMID: 19228401.
21. Lak M et al. (2025) Does creatine cause hair loss? 12-week RCT. JISSN. PMID: 40265319. NO effect on DHT or hair loss.
22. Garcia MP et al. (2025) Long-term creatine safety in women's football players. JISSN. PMID: 41328005.
23. Korovljev D et al. (2026) CONCRET-MENOPA: creatine in perimenopausal/menopausal women. J Am Nutr Assoc. PMID: 40854087.
24. Slankamenac J et al. (2024) Creatine-glucose alleviates Long COVID features. J Nutr Sci Vitaminol. PMID: 38684388.

Safety Studies

25. Kreider RB et al. (2003) 21-month creatine use: no adverse effects. Mol Cell Biochem 244:95-104. PMID: 12701815. N=98 athletes.
26. Gualano B et al. (2008) Creatine in T2D: kidney safety RCT. Eur J Appl Physiol 103(1):33-40. PMID: 17891414. 10 g/d × 3 mo: no renal impairment.
27. Greenwood M et al. (2003) Creatine users had FEWER cramps/injuries. J Athl Train 38(3):216-219. PMID: 14608430.

Cognitive & Neuroprotection

28. Rae C et al. (2003) Creatine improves brain performance in vegetarians. Proc R Soc B 270:2147-2150. PMID: 14561278.
29. McMorris T et al. (2007) Creatine + cognitive performance in elderly. Aging Neuropsychol Cogn 14(5):517-528. PMID: 17828627.
30. Sakellaris G et al. (2006) Creatine in pediatric TBI. J Trauma 61(2):322-329. PMID: 16917449. 68% shorter hospitalization, 50% shorter ICU.
31. Kious BM et al. (2019) Creatine for depression treatment. Biomolecules 9(9):406. PMID: 31455028. d=0.3-0.5 with SSRIs.
32. Dolan E et al. (2019) Beyond muscle: creatine on brain, cognition, TBI. Eur J Sport Sci 19(1):1-14. PMID: 29719201.
33. Candow DG et al. (2026) Creatine and the brain: cart before the horse? J Diet Suppl. PMID: 41556609.
34. Howell DR et al. (2026) Brain creatine, sex, and concussion severity. Brain Inj. PMID: 41504207.

Disease-Specific

35. NINDS NET-PD (2015) Creatine in early Parkinson's: negative Phase III. Neurology 85(9):781-788. PMID: 26275043. N=1,741; terminated for futility.
36. Gualano B et al. (2010) Creatine + aerobic training on glucose tolerance. Amino Acids 34(2):245-250. PMID: 19437111.
37. Gualano B et al. (2012) Creatine in muscle wasting conditions. Amino Acids 43(2):519-529. PMID: 22101982.
38. Candow DG et al. (2019) Creatine on aging muscle and bone. J Clin Med 8(4):488. PMID: 30959901.
39. Młynarska E et al. (2025) Creatine + exercise for T2D prevention. Nutrients. PMID: 40944248.
40. Moreira-Velasco JE et al. (2025) Creatine in osteosarcopenia. Nutrients. PMID: 40732957.

Mechanistic & Genetic

41. Wallimann T et al. (2011) Creatine kinase system and pleiotropic effects. Amino Acids 40(5):1271-1296. PMID: 21448658.
42. Wyss M, Kaddurah-Daouk R (2000) Creatine and creatinine metabolism. Physiol Rev 80(3):1107-1213. PMID: 10893433.
43. Jäger R et al. (2011) Novel forms of creatine: efficacy, safety, regulatory status. Amino Acids 40(5):1369-1383. PMID: 21394604.
44. Bender A et al. (2006) Creatine improves health and survival in mice. Neurobiol Aging 29(9):1404-1411. PMID: 17416440. +9% lifespan.
45. Cornelissen VA et al. (2010) Creatine in cardiac patients. Clin Rehabil 24(11):988-999. PMID: 20685719.
46. Ostojic SM, Kavecan I (2026) Genetic determinants of creatine bioavailability. Lifestyle Genom. PMID: 41719210.
47. Alessandrì MG et al. (2026) Creatine transporter deficiency: Italian cohort. Orphanet J Rare Dis. PMID: 41776642.
48. Zhang Y et al. (2026) L-Arginine + creatine on hippocampal neurogenesis. Mol Neurobiol. PMID: 41514140.
49. Lu CL et al. (2026) Gut microbiota alleviates depression via creatine metabolism. Cell Metab. PMID: 41923613.

TBI Reviews

50. Lucke-Wold B et al. (2025) Supplement therapy in TBI. Nutr Neurosci. PMID: 40440029.
51. Vietor FI et al. (2025) TBI pathophysiology and creatine rationale. Mo Med. PMID: 39958598.
52. Conti F et al. (2024) Pre-loading creatine for concussion neuroprotection. Reference in existing file.

Exercise Performance

53. Bemben MG, Lamont HS (2005) Creatine and exercise performance. Sports Med 35(2):107-125. PMID: 15707376. 100+ studies; +5-15% high-intensity performance.
54. Cribb PJ, Hayes A (2006) Post-exercise creatine timing. PMID: 16807907. Post > pre for body composition.